Given the good results observed, randomized clinical trials were conducted comparing chemotherapy with first-line immunomodulators for patients with NSCLC (such as Keynote 024 or CheckMate 026); based on the expression of PD-L1, the studies revealed the usefulness and possible limitations of immunomodulators, consolidating the evidence with regard to the use of immunotherapy in different neoplasms [25,26]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.